MXPA04008216A - Anticuerpo monoclonal tenascina anti-humano. - Google Patents

Anticuerpo monoclonal tenascina anti-humano.

Info

Publication number
MXPA04008216A
MXPA04008216A MXPA04008216A MXPA04008216A MXPA04008216A MX PA04008216 A MXPA04008216 A MX PA04008216A MX PA04008216 A MXPA04008216 A MX PA04008216A MX PA04008216 A MXPA04008216 A MX PA04008216A MX PA04008216 A MXPA04008216 A MX PA04008216A
Authority
MX
Mexico
Prior art keywords
antibody
tenascin
fragments
tumor
biotinylated
Prior art date
Application number
MXPA04008216A
Other languages
English (en)
Spanish (es)
Inventor
Maria Anastasi Anna
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Publication of MXPA04008216A publication Critical patent/MXPA04008216A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
MXPA04008216A 2002-02-26 2003-02-20 Anticuerpo monoclonal tenascina anti-humano. MXPA04008216A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35929902P 2002-02-26 2002-02-26
PCT/IT2003/000098 WO2003072608A1 (en) 2002-02-26 2003-02-20 Anti-human tenascin monoclonal antibody

Publications (1)

Publication Number Publication Date
MXPA04008216A true MXPA04008216A (es) 2004-11-26

Family

ID=27766061

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04008216A MXPA04008216A (es) 2002-02-26 2003-02-20 Anticuerpo monoclonal tenascina anti-humano.

Country Status (19)

Country Link
US (3) US7438908B2 (https=)
EP (1) EP1478667B1 (https=)
JP (1) JP4488746B2 (https=)
KR (1) KR101048894B1 (https=)
CN (1) CN1317303C (https=)
AR (1) AR038700A1 (https=)
AT (1) ATE480564T1 (https=)
AU (1) AU2003215900B2 (https=)
BR (1) BR0307994A (https=)
CA (1) CA2475395C (https=)
CY (1) CY1111108T1 (https=)
DE (1) DE60334076D1 (https=)
DK (1) DK1478667T3 (https=)
ES (1) ES2352180T3 (https=)
MX (1) MXPA04008216A (https=)
PL (1) PL213216B1 (https=)
PT (1) PT1478667E (https=)
SI (1) SI1478667T1 (https=)
WO (1) WO2003072608A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20040105A1 (it) * 2004-02-27 2004-05-27 Tecnogen Scpa Anticorpo monoclonale antitenascina umana.
EP2057193B1 (en) 2006-08-04 2013-12-18 Novartis AG Ephb3-specific antibody and uses thereof
CA2711843C (en) 2007-12-20 2018-11-13 Laboratory Corporation Of America Holdings Her-2 diagnostic methods
FR2930036B1 (fr) * 2008-04-11 2010-05-07 Assist Publ Hopitaux De Paris Procede de diagnostic d'une hypertension arterielle pulmonaire.
US8187601B2 (en) * 2008-07-01 2012-05-29 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (FGFR3) binding proteins
US8470542B2 (en) 2008-12-01 2013-06-25 Laboratory Corporation Of America Holdings Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95
SG172983A1 (en) 2009-01-15 2011-08-29 Lab Corp America Holdings Methods of determining patient response by measurement of her-3
SG172984A1 (en) * 2009-01-15 2011-08-29 Lab Corp America Holdings Methods of determining patient response by measurement of her-2 expression
US10266585B2 (en) 2009-08-28 2019-04-23 The Board Of Regents Of The Univerity Of Texas System Methods of treating brain injury
WO2011060076A1 (en) * 2009-11-10 2011-05-19 Amgen Inc. Anti-c-mpl antibodies
WO2012051498A2 (en) 2010-10-15 2012-04-19 The Board Of Regents Of The University Of Texas System Antibodies that bind amyloid oligomers
US8959638B2 (en) 2011-03-29 2015-02-17 Mcafee, Inc. System and method for below-operating system trapping and securing of interdriver communication
US8966624B2 (en) 2011-03-31 2015-02-24 Mcafee, Inc. System and method for securing an input/output path of an application against malware with a below-operating system security agent
US9032525B2 (en) 2011-03-29 2015-05-12 Mcafee, Inc. System and method for below-operating system trapping of driver filter attachment
US9262246B2 (en) 2011-03-31 2016-02-16 Mcafee, Inc. System and method for securing memory and storage of an electronic device with a below-operating system security agent
US8863283B2 (en) 2011-03-31 2014-10-14 Mcafee, Inc. System and method for securing access to system calls
US9087199B2 (en) 2011-03-31 2015-07-21 Mcafee, Inc. System and method for providing a secured operating system execution environment
US9038176B2 (en) 2011-03-31 2015-05-19 Mcafee, Inc. System and method for below-operating system trapping and securing loading of code into memory
US9317690B2 (en) 2011-03-28 2016-04-19 Mcafee, Inc. System and method for firmware based anti-malware security
US8966629B2 (en) 2011-03-31 2015-02-24 Mcafee, Inc. System and method for below-operating system trapping of driver loading and unloading
US8813227B2 (en) 2011-03-29 2014-08-19 Mcafee, Inc. System and method for below-operating system regulation and control of self-modifying code
US8925089B2 (en) 2011-03-29 2014-12-30 Mcafee, Inc. System and method for below-operating system modification of malicious code on an electronic device
US9255595B2 (en) * 2011-04-29 2016-02-09 Bae Systems Information And Electronic Systems Integration Inc. Optical dome bezel
WO2013088140A2 (en) * 2011-12-12 2013-06-20 Isis Innovation Limited Biomarker and use thereof
US9657098B2 (en) 2013-03-15 2017-05-23 Intrinsic Lifesciences, Llc Anti-hepcidin antibodies and uses thereof
GB201414021D0 (en) * 2014-08-07 2014-09-24 Nascient Ltd Biological materials and uses thereof
AU2015321462B2 (en) 2014-09-22 2020-04-30 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
GB201602413D0 (en) * 2016-02-10 2016-03-23 Nascient Ltd Method

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4687732A (en) * 1983-06-10 1987-08-18 Yale University Visualization polymers and their application to diagnostic medicine
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994021293A1 (en) * 1993-03-19 1994-09-29 Duke University Method of treatment of tumors with an antibody binding to tenascin
US5482698A (en) * 1993-04-22 1996-01-09 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin polymer conjugates
ATE335072T1 (de) * 1993-05-28 2006-08-15 Scripps Research Inst Methoden für inhibition der cd14-abhängigen zellaktivierung
US6335014B1 (en) * 1998-06-17 2002-01-01 The Institute Of Physical And Chemical Research Medicament for suppressing cancer metastasis
ITRM20020128A1 (it) 2002-03-08 2003-09-08 Sigma Tau Ind Farmaceuti Dimeri di avidina efficaci nell'incrementare la concentrazione di biotina radioattiva nella immunoterapia con "pretargeting".

Also Published As

Publication number Publication date
KR20040086426A (ko) 2004-10-08
PL213216B1 (pl) 2013-01-31
AU2003215900B2 (en) 2008-09-25
AU2003215900A1 (en) 2003-09-09
SI1478667T1 (sl) 2010-12-31
CN1639192A (zh) 2005-07-13
CN1317303C (zh) 2007-05-23
EP1478667A1 (en) 2004-11-24
JP2005534615A (ja) 2005-11-17
KR101048894B1 (ko) 2011-07-13
ES2352180T3 (es) 2011-02-16
JP4488746B2 (ja) 2010-06-23
DE60334076D1 (de) 2010-10-21
US20110020219A1 (en) 2011-01-27
US20040005643A1 (en) 2004-01-08
CY1111108T1 (el) 2015-06-11
US8048417B2 (en) 2011-11-01
PT1478667E (pt) 2010-12-09
EP1478667B1 (en) 2010-09-08
PL372803A1 (en) 2005-08-08
US20050106145A1 (en) 2005-05-19
WO2003072608A1 (en) 2003-09-04
ATE480564T1 (de) 2010-09-15
AR038700A1 (es) 2005-01-26
CA2475395C (en) 2011-08-02
CA2475395A1 (en) 2003-09-04
BR0307994A (pt) 2004-12-07
US7438908B2 (en) 2008-10-21
HK1078589A1 (en) 2006-03-17
DK1478667T3 (da) 2010-12-20

Similar Documents

Publication Publication Date Title
US8048417B2 (en) Anti-human tenascin monoclonal antibody
CN116003598B (zh) 靶向人gprc5d的重组人源化单克隆抗体及其应用
JP2001521520A (ja) 抗α▲下ｖ▼β▲下３▼インテグリン抗体アンタゴニスト
US12565534B2 (en) Nano-antibody targeting CAIX antigen and application thereof
JP2024514855A (ja) Ｄｌｌ３に対する結合分子及びその使用
US20250304681A1 (en) Anti-rage antibody, extracellular vesicle, and preparation method and use thereof
US7384631B2 (en) Methods of diagnosis and treatment by binding p75/AIRM1
JP5191036B2 (ja) 抗ヒトテネイシンモノクローナル抗体
CN116574187B (zh) 针对gucy2c的抗体及其用途
CN113321730B (zh) Cldn18.2抗体及其应用
WO2025035356A1 (en) Antibodies against dll3 and uses thereof
WO2025051254A1 (zh) 半胱氨酸改造的抗体和免疫缀合物
HK40098522B (zh) 针对dll3的抗体及其用途
HK40098522A (zh) 针对dll3的抗体及其用途
HK1100848B (en) Anti-human tenascin monoclonal antibody

Legal Events

Date Code Title Description
FG Grant or registration